222 related articles for article (PubMed ID: 30204305)
21. Synthesis of naphthazarin derivatives and identification of novel thioredoxin reductase inhibitor as potential anticancer agent.
Zhang J; Liu Y; Shi D; Hu G; Zhang B; Li X; Liu R; Han X; Yao X; Fang J
Eur J Med Chem; 2017 Nov; 140():435-447. PubMed ID: 28987605
[TBL] [Abstract][Full Text] [Related]
22. Thioredoxin system modulation by plant and fungal secondary metabolites.
Dal Piaz F; Braca A; Belisario MA; De Tommasi N
Curr Med Chem; 2010; 17(5):479-94. PubMed ID: 19941471
[TBL] [Abstract][Full Text] [Related]
23. Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung.
Ozgencli I; Budak H; Ciftci M; Anar M
Anticancer Agents Med Chem; 2018; 18(11):1599-1605. PubMed ID: 29793415
[TBL] [Abstract][Full Text] [Related]
24. Thioredoxin reductase inhibitors: a patent review.
Zhang B; Zhang J; Peng S; Liu R; Li X; Hou Y; Han X; Fang J
Expert Opin Ther Pat; 2017 May; 27(5):547-556. PubMed ID: 27977313
[TBL] [Abstract][Full Text] [Related]
25. Securinine disturbs redox homeostasis and elicits oxidative stress-mediated apoptosis via targeting thioredoxin reductase.
Zhang J; Yao J; Peng S; Li X; Fang J
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):129-138. PubMed ID: 27777067
[TBL] [Abstract][Full Text] [Related]
26. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
Ng HL; Chen S; Chew EH; Chui WK
Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
[TBL] [Abstract][Full Text] [Related]
27. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Lu J; Chew EH; Holmgren A
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Thioredoxin System as a Strategy for Cancer Therapy.
Bian M; Fan R; Zhao S; Liu W
J Med Chem; 2019 Aug; 62(16):7309-7321. PubMed ID: 30963763
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Thioredoxin Reductase by Triosmium Carbonyl Clusters.
Koh WX; Coppo L; Holmgren A; Kong JW; Leong WK
Chem Res Toxicol; 2020 Sep; 33(9):2441-2445. PubMed ID: 32786549
[TBL] [Abstract][Full Text] [Related]
30. Thiol antioxidant thioredoxin reductase: A prospective biochemical crossroads between anticancer and antiparasitic treatments of the modern era.
Joardar N; Guevara-Flores A; Martínez-González JJ; Sinha Babu SP
Int J Biol Macromol; 2020 Dec; 165(Pt A):249-267. PubMed ID: 32961182
[TBL] [Abstract][Full Text] [Related]
31. Can Selenoenzymes Resist Electrophilic Modification? Evidence from Thioredoxin Reductase and a Mutant Containing α-Methylselenocysteine.
Ste Marie EJ; Wehrle RJ; Haupt DJ; Wood NB; van der Vliet A; Previs MJ; Masterson DS; Hondal RJ
Biochemistry; 2020 Sep; 59(36):3300-3315. PubMed ID: 32845139
[TBL] [Abstract][Full Text] [Related]
32. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
Wipf P; Lynch SM; Birmingham A; Tamayo G; Jiménez A; Campos N; Powis G
Org Biomol Chem; 2004 Jun; 2(11):1651-8. PubMed ID: 15162219
[TBL] [Abstract][Full Text] [Related]
33. In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury.
Wagner C; Sudati JH; Nogueira CW; Rocha JB
Biometals; 2010 Dec; 23(6):1171-7. PubMed ID: 20717703
[TBL] [Abstract][Full Text] [Related]
34. Thioredoxin reductase and its inhibitors.
Saccoccia F; Angelucci F; Boumis G; Carotti D; Desiato G; Miele AE; Bellelli A
Curr Protein Pept Sci; 2014; 15(6):621-46. PubMed ID: 24875642
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.
Liu X; Pietsch KE; Sturla SJ
Chem Res Toxicol; 2011 May; 24(5):726-36. PubMed ID: 21443269
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
37. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples.
Montano SJ; Lu J; Gustafsson TN; Holmgren A
Anal Biochem; 2014 Mar; 449():139-46. PubMed ID: 24374250
[TBL] [Abstract][Full Text] [Related]
38. Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors.
Cheng Y; Qi Y
Anticancer Agents Med Chem; 2017; 17(8):1046-1069. PubMed ID: 28270080
[TBL] [Abstract][Full Text] [Related]
39. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
Gandin V; Fernandes AP
Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
[TBL] [Abstract][Full Text] [Related]
40. Thioredoxin reductase inhibitors: updated patent review (2017-present).
Chupakhin E; Krasavin M
Expert Opin Ther Pat; 2021 Aug; 31(8):745-758. PubMed ID: 33666133
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
